Dr. Reddy's Laboratories Launches Avigan in India
19 August 2020 - - India-based Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Avigan (Favipiravir) 200 mg Tablets in India, the company said.

The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co. Ltd. that grants Dr. Reddy's the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India.

Avigan (Favipiravir) has been approved by the Drugs Controller General of India for the treatment of patients with mild to moderate COVID-19 disease.

Dr. Reddy's AVIGAN comes in a complete therapy pack of 122 tablets with a two-year shelf life.

To ensure accelerated access to the medicine, Dr. Reddy's has initiated a free home delivery service in 42 cities in the country, and a Helpline Center.

Dr. Reddy's Laboratories) is an integrated pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.